Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Cholestasis Stories

2014-04-14 10:59:02

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to...

2013-11-18 08:28:41

Company receives first positive opinion in the European Union for Primary Sclerosing Cholangitis SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has received positive opinions for four Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for LUM001. The company's lead drug candidate, LUM001, received the first positive...

2013-11-05 08:34:31

Data Presented Today at Annual Meeting of the American Association for the Study of Liver Diseases in Washington DC Provides Additional Preclinical Validation for LUM001 Currently Being Evaluated in Phase II Studies in Multiple Cholestatic Liver Disease Populations SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for cholestatic liver diseases, today announced that inhibition of the apical sodium-dependent bile acid transporter...

2013-10-29 08:32:43

Novel therapeutic approach to be evaluated for its ability to reduce elevated bile acid levels and associated severe itching SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the dosing of the first patient in the CLARITY Phase II study of its drug candidate LUM001 in patients with primary biliary cirrhosis (PBC). LUM001 is being developed as a possible therapy for a number of cholestatic...

2013-09-26 08:27:28

First patient dosed in U.K. in Phase II IMAGO Study; Phase II ITCH Study to start in U.S. SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome (ALGS). The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric...

2013-09-26 08:27:25

Company Pursuing Orphan Path to Development in Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development for LUM001, the company's lead...

2013-05-08 08:29:58

Funding to support clinical development of drug candidates to treat rare liver diseases SAN DIEGO, May 8, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the company has secured $23 million in Series A financing. Investors include Pappas Ventures, RiverVest Venture Partners and Alta Partners. Founded in 2011 by Pappas Ventures, Lumena will primarily use the funding to advance the clinical development of...

2012-11-08 04:22:50

GOTHENBURG, Sweden, November 8, 2012 /PRNewswire/ -- Albireo AB (Gothenburg, Sweden; "Albireo"), a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of - Progressive Familial Intrahepatic Cholestasis (PFIC) - Primary Biliary Cirrhosis (PBC)...

2012-07-23 22:20:40

GOTHENBURG, Sweden, July 24, 2012 /PRNewswire/ -- Albireo AB (Gothenburg, Sweden; "Albireo"), a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250, for the treatment of: - Primary Biliary Cirrhosis (PBC) -...

Turning Off Key Piece Of Genetic Coding Eliminates Toxic Effect Of Statins
2012-07-09 17:08:26

Study Sheds Light on Cholesterol and Bile Metabolism in the Liver In research funded by the National Institutes of Health and the American Heart Association and published in EMBO Molecular Medicine, Saint Louis University investigator Ángel Baldán, Ph.D., found that the microRNA miR-33 plays a key role in regulating bile metabolism. Further, the research suggests that, in an animal model, the manipulation of this microRNA can improve the liver toxicity that can...